TICKERNERD
Menu
CLBTCLBTTechnology · Software - Infrastructure

CLBT Stock Forecast: Cellebrite DI Ltd. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$11
+3.15% on the day

The 7 Wall Street analysts covering Cellebrite DI Ltd. hold a median 12-month price target of $21 — +88.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$2.8B
Ticker Nerd rank
50 / 100
Median analyst target
$21
Analysts covering
7
Total return, dividends reinvested
1W
−30.4%
1M
−31.1%
YTD
−38.2%
1Y
−27.1%
From 52W high
−43.0%
From 52W low
+3.1%
$11
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLBT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cellebrite DI Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
91
Growth
69
Accruals
62
Value
59
Momentum
41
Volatility
38
Revisions
37
Issuance
36
Size
33

Quality (91): The business earns solid, repeatable profits on what it owns.

Issuance (36): The company has been issuing shares or taking on financing, diluting existing holders.

Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLBT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLBT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26CLBTHigh $28Median $21Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $15Median $21High $28

The green dot is the last close — the median target sits +88.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
14 Aug 2026DA DavidsonMaintainsBuy$22 → $15
14 Aug 2026JP MorganMaintainsOverweight$20 → $16
14 Aug 2026Lake StreetMaintainsBuy$21 → $15
14 Aug 2026NeedhamMaintainsBuy$15 → $13
6 Aug 2026DA DavidsonMaintainsBuy$20 → $22
27 May 2026DA DavidsonInitiatesBuy$20
27 May 2026DA DavidsonInitiatesBuy—
15 May 2026NeedhamMaintainsBuy—
12 Feb 2026NeedhamMaintainsBuy—
13 Nov 2025B of A SecuritiesMaintainsBuy—
13 Nov 2025JP MorganMaintainsOverweight—
13 Nov 2025Lake StreetMaintainsBuy—
13 Nov 2025NeedhamMaintainsBuy—
24 Sept 2025JP MorganMaintainsOverweight—
15 Aug 2025Lake StreetMaintainsBuy—
14 Aug 2025NeedhamMaintainsBuy—
23 June 2025JP MorganMaintainsOverweight—
6 June 2025NeedhamReiteratesBuy—
15 May 2025JP MorganMaintainsOverweight—
14 May 2025NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLBT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CLBT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.7%
Analysts raising
4
Analysts cutting
1
Fundamentals

Cellebrite DI Ltd. (CLBT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
48.4×

Cheaper than 16% of US stocks

Price / sales
5.4×

Cheaper than 23% of US stocks

Price / book
5.2×

Cheaper than 21% of US stocks

EV / EBITDA
30.3×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
15.8%

Higher than 64% of US stocks

Earnings growth (YoY)
−67.3%

Higher than 7% of US stocks

Gross margin
82.5%

Higher than 92% of US stocks

Operating margin
5.3%

Higher than 56% of US stocks

Net margin
11.4%

Higher than 73% of US stocks

Returns & dividend
Return on equity
12.4%

Higher than 69% of US stocks

Return on assets
3.9%

Higher than 70% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CLBT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSoftware - Infrastructure
CompanyMarket capTKN rank
CLBTCellebrite DI Ltd.$2.8B
50
APPNAppian Corp.$2.6B
96
TDCTeradata Corp.$2.6B
98
EEFTEuronet Worldwide, Inc.$2.8B
54
INFQInfleqtion, Inc.$2.8B
9
PAGSPagSeguro Digital Ltd.$2.5B
61
FIVNFive9, Inc.$2.5B
84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cellebrite DI Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLBT news & analysis

Cellebrite DI Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Cellebrite DI (CLBT)

PRNewsWire · 14 Aug 2026negative

Shareholders of Cellebrite DI Ltd. (CLBT) lost money when the stock fell more than 30% after the company's Q2 2026 results. Levi & Korsinsky has notified investors that it is investigating the company's disclosures concerning its previous projections and related discussions.

Why it matters — CLBT watchers would care because the firm is facing a formal investigation into its disclosures following a sharp post-earnings decline, raising questions about the accuracy of its earlier projections.

Kaplan Fox Alerts Investors of Cellebrite DI Ltd. (CLBT) to an Investigation of Potential Securities Law Violations

Newsfile Corp · 13 Aug 2026negative

Kaplan Fox & Kilsheimer LLP announced an investigation into potential securities law violations against Cellebrite DI Ltd. (NASDAQ: CLBT). The law firm is examining whether the company may have violated securities laws, as disclosed in an August 13, 2026 news release.

Why it matters — CLBT watchers would care because an active securities investigation could lead to legal or reputational consequences for the company.

Cellebrite DI Ltd. (CLBT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Seeking Alpha published the transcript of Cellebrite DI Ltd.'s (CLBT) Q2 2026 earnings call. The item presents the earnings call transcript for the second quarter of fiscal 2026.

Why it matters — A CLBT watcher would care because the transcript provides direct insight into the company's latest quarterly results and management commentary.

Cellebrite Q2: This 33% Selloff Looks Like An Overreaction

Seeking Alpha · 13 Aug 2026positive

Cellebrite's stock fell 33% after Q2 earnings, which missed ARR and revenue guidance and included a management transition and slower Inseyets conversions, though the article argues this was an overreaction given strong fundamentals.

Why it matters — The piece suggests the selloff is excessive because Cellebrite still has high gross margins, strong free cash flow, and high-teens revenue growth guidance, which matters for investors weighing whether the drop presents a buying opportunity versus a warning sign.

CLBT INVESTIGATION: Cellebrite DI Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Possibly Recover Losses

Newsfile Corp · 13 Aug 2026negative

Block & Leviton has announced it is investigating Cellebrite DI (NASDAQ: CLBT) for potential securities law violations, according to a Newsfile Corp release dated August 13, 2026. The law firm is asking investors who have lost money in Cellebrite DI to contact them about possibly recovering losses.

Why it matters — A securities fraud investigation could signal legal and reputational concerns for Cellebrite DI that current and prospective investors may want to monitor.

FAQ

Frequently asked questions about CLBT stock

What is the CLBT stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Cellebrite DI Ltd. have a median 12-month price target of $21, with estimates ranging from $15 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLBT stock a buy right now?

Of the 7 analysts covering Cellebrite DI Ltd., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cellebrite DI Ltd. 50 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLBT?

As at 15 Aug 2026, Cellebrite DI Ltd. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (91 of 100).

Will CLBT stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +88.5% from the last close, and Ticker Nerd's factor model ranks Cellebrite DI Ltd. 50 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLBT stock forecast for 2030?

No analyst covering Cellebrite DI Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLBT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $28 over the next 12 months.

How has CLBT stock performed over the past year?

Cellebrite DI Ltd. returned -27.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cellebrite DI Ltd. do?

Cellebrite DI Ltd. is an Israeli digital intelligence company headquartered in Petah Tikva, providing advanced solutions for legally sanctioned digital investigations worldwide.

What is the latest news on CLBT?

The most recent item we track (PRNewsWire, 14 Aug 2026): "Cellebrite DI Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Cellebrite DI (CLBT)". Shareholders of Cellebrite DI Ltd. (CLBT) lost money when the stock fell more than 30% after the company's Q2 2026 results. Levi & Korsinsky has notified investors that it is investigating the company's disclosures concerning its previous projections and related discussions.

Company

About Cellebrite DI Ltd.

Cellebrite DI Ltd. is an Israeli digital intelligence company headquartered in Petah Tikva, providing advanced solutions for legally sanctioned digital investigations worldwide. Its core offerings include the DI suite, which enables users to access, collect, review, extract, decode, decrypt, analyze, share, and manage digital data across the investigative lifecycle from sources like mobile devices, computers, drones, SIM cards, GPS devices, social media, and cloud platforms. Notable products such as Inseyets facilitate the collection and review of digital evidence, while tools like the Universal Forensic Extraction Device (UFED) support extraction from a wide array of devices, including those with advanced security like Apple T2 chips. Cellebrite DI Ltd. serves law enforcement at federal, state, and local levels, military and intelligence agencies, immigration authorities, prison systems, and enterprise customers tackling cases involving child exploitation, homicide, terrorism, organized crime, human trafficking, corporate security, cryptocurrency investigations, and intellectual property theft. The company also delivers analytics, training, and services to enhance efficiency in public safety and private sector operations, positioning it as a leader in digital forensics and investigative technologies.

CEO Mr. Thomas E. Hogan · 1,167 employees · Israel · https://www.cellebrite.com